Malanil® Paediatric Tablets – Expands the antimalarial chemoprophylaxis options for children

  • Editorial Office Medpharm Publications
Keywords: Malanil® Paediatric Tablets, antimalarial chemoprophylaxis

Abstract

Ideally, infants and children under 5 years of age should not travel to malaria areas.1 However, if travel to a malaria risk area is essential, then antimalarial chemoprophylaxis is indicated.1 The paediatric combination of atovaquone and proguanil is a welcome addition to the antimalarial chemoprophylaxis options available for use in children. Malanil® Paediatric Tablets contain 62.5 mg atovaquone and 25 mg proguanil per tablet.2 The product is indicated for the prophylaxis of drug sensitive and drug resistant Plasmodium falciparum malaria.2 Official local and international malaria chemoprophylaxis guidelines should be consulted at least two weeks before intended travel to establish the risk of malaria in a particular area.2
Section
New Product Focus